Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

1.890 +0.200 (+11.83%)
Official Closing Price Updated: 4:10 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 Next >
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Present at Upcoming Investor Conferences
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.